The invention patent of CD47xVEGF mAb-Trap was authorized by China Intellectual Property Office

On December 21, 2020, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that its CD47xVEGF MAb Trap (company project No.: IMM02) recently obtained the invention patent authorization from China Intellectual Property Office (China patent applicatio......

2020-12-21

Heavy weight! 93 key projects of Zhangjiang Science City were signed, and the headquarters of ImmuneOnco was listed as one of the key projects

On the morning of December 18, 2020, the signing and launching ceremony of key projects of Zhangjiang Science City will be held in Zhangjiang. Focusing on the online new economy, the event focused on the three major industries of integrated circuit, biomedi......

2020-12-18

The patent of CD47xPD-L1 bispecific antibody was authorized by US patent office

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the self-developed bispecific antibody drug (Project No.: IMM2505) targeting both CD47 and PD-L1 was recently authorized by the U.S. Patent Office (application No.: 16/170024). The invention ......

2020-12-15

The IMM0306 project of ImmuneOnco was accepted by FDA for clinical trial

On December 10, 2020, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the bispecific antibody drug (Project No.: IMM0306) independently developed by the company and targeting CD47 and CD20 simultaneously has obtained the application(Applic......

2020-12-10

Clinical trial study on expanding new indications of IMM01 project

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first Fc fusion protein drug targeting human CD47 (project number: IMM01) in China was accepted by NMPA for clinical trial application (IND) for new indications (MM, AML and MDS). This is......

2020-11-21